Brokerages Expect TherapeuticsMD Inc (TXMD) to Post ($0.11) EPS
TherapeuticsMD Inc (NASDAQ:TXMD) has been given a consensus broker rating score of 1.00 (Strong Buy) from the four analysts that provide coverage for the stock, Zacks Investment Research reports. Four investment analysts have rated the stock with a strong buy rating.
Brokers have set a 12-month consensus price objective of $15.63 for the company and are forecasting that the company will post ($0.11) EPS for the current quarter, according to Zacks. Zacks has also given TherapeuticsMD an industry rank of 156 out of 265 based on the ratings given to related companies.
TXMD has been the topic of several analyst reports. Zacks Investment Research upgraded shares of TherapeuticsMD from a “sell” rating to a “hold” rating in a report on Thursday, September 22nd. Noble Financial reiterated a “buy” rating and set a $17.50 price target on shares of TherapeuticsMD in a report on Monday, July 11th.
Shares of TherapeuticsMD (NASDAQ:TXMD) traded down 1.73% during trading on Friday, hitting $6.24. 587,611 shares of the company’s stock were exchanged. The stock’s market cap is $1.23 billion. TherapeuticsMD has a one year low of $5.18 and a one year high of $11.26. The firm has a 50-day moving average price of $6.69 and a 200-day moving average price of $7.66.
TherapeuticsMD (NASDAQ:TXMD) last posted its earnings results on Thursday, August 4th. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by $0.01. The firm had revenue of $4.40 million for the quarter, compared to analysts’ expectations of $5.63 million. During the same quarter in the previous year, the business posted ($0.16) EPS. The firm’s revenue was down 8.3% on a year-over-year basis. Equities research analysts expect that TherapeuticsMD will post ($0.43) EPS for the current fiscal year.
TherapeuticsMD, Inc is a women’s healthcare product company. The Company’s segment is creating and commercializing products for women. It is focused on conducting clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. Its drug candidates are created using its SYMBODA hormone technology, which enables the administration of hormones with high bioavailability alone or in combination.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with MarketBeat.com's FREE daily email newsletter.